The film is structured in three main acts:
| Region | Status (as of 2024) | |--------|--------------------| | | Not specifically scheduled at the federal level, but may be treated as an analogue under the Federal Analogue Act if intended for human consumption. Several states (e.g., California, Ohio) have listed it under “designer‑drug” schedules. | | European Union | Not listed in the EU Early Warning System, but flagged in the EMCDDA “New Psychoactive Substances” alerts. Some member states have provisional bans. | | Canada | Not scheduled, but could be prosecuted under the “controlled‑substances analogue” provisions. | | Australia | Not listed in the Poisons Standard; however, the TGA monitors it as a “potentially harmful substance.” | | International | No UN‑controlled schedule. The WHO Expert Committee on Drug Dependence has not yet evaluated it. | JUQ-063
Dedicated buttons allow you to switch between piano, organ, violin, and hundreds of other sound effects. The film is structured in three main acts:
Below is an overview of how codes like JUQ-063 are structured, tracked, and utilized across different commercial markets. 🎥 Media and Entertainment Distribution Some member states have provisional bans
| Phase | Trial ID | Design | Population | Primary Endpoint | Status (as of Apr 2026) | |-------|----------|--------|------------|------------------|------------------------| | | NCT05873201 | Open‑label, dose escalation (3 + 3) → RP2D identification | Advanced solid tumors harboring KRAS G12D (PDAC, CRC, NSCLC) | Safety, MTD, PK/PD, ORR (exploratory) | Completed (2025); RP2D = 30 mg QD | | Phase Ib/IIa | NCT05984212 | Cohort expansion + pembrolizumab combo (PD‑1 blockade) | KRAS G12D‑mutant PDAC, previously treated | ORR, DCR, PFS (12‑wk) | Ongoing (enrollment 70 % complete) | | Phase IIb | NCT06000123 | Randomized (1:1) JUQ‑063 + standard gemcitabine/nab‑paclitaxel vs. standard chemo alone | Treatment‑naïve KRAS G12D PDAC | PFS, OS, safety | Initiated Q3 2025 | | Phase III (Planned) | NCT06123456 | Global, double‑blind, JUQ‑063 + chemo ± immunotherapy vs. chemo + immunotherapy | Metastatic KRAS G12D PDAC | OS (primary), PFS, QoL | Protocol development 2026, IND filing Q4 2026 |